Merus N.V. (MRUS)

18.40 +0.22 (+1.21%) At close: 04:00PM EDT

Merus N.V.

Yalelaan 62
Utrecht 3584 CM
Netherlands
31 30 253 8800
https://www.merus.nl

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Sven Ante Lundberg M.D.	CEO, Pres, Principal Financial Officer & Exec. Director	990.53k	N/A	1963
Mr. Peter B. Silverman J.D.	Exec. VP, COO, Gen. Counsel, Chief Intellectual Property Officer & Head of US Legal	677.96k	N/A	1978
Mr. Hui Liu Ph.D.	Chief Bus. Officer, Exec. VP & Head of Merus U.S.	605.93k	N/A	1967
Dr. Hennie Hoogenboom	Co-Founder and Scientific Advisor	N/A	N/A	N/A
Harry Shuman	Chief Accounting Officer	N/A	N/A	N/A
Mr. Cornelis Adriaan de Kruif Ph.D.	CTO & Exec. VP	N/A	N/A	1965
Dr. Cecilia Anna Wilhelmina Geuijen Ph.D.	Chief Scientific Officer & Sr. VP	N/A	N/A	N/A
Ms. Jillian Connell	VP of Investor Relations & Corp. Communications	N/A	N/A	N/A
Mr. Alexander Berthold Hendrik Bakker Ph.D.	Chief Devel. Officer & Exec. VP	N/A	N/A	1967
Dr. Andrew Joe M.D.	Chief Medical Officer & Sr. VP	N/A	N/A	1967

Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

Corporate governance

Merus N.V.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.